Ability of Recombinant Human Bone Morphogenetic Protein 2 to Enhance Bone Healing in the Presence of Tobramycin: Evaluation in a Rat Segmental Defect Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Glatt, Vaida | - |
dc.contributor.author | Kwong, Francois N. | - |
dc.contributor.author | Park, Kichul | - |
dc.contributor.author | Parry, Nicola | - |
dc.contributor.author | Griffin, Damian | - |
dc.contributor.author | Vrahas, Mark | - |
dc.contributor.author | Evans, Christopher H. | - |
dc.contributor.author | Harris, Mitchel | - |
dc.date.accessioned | 2022-12-20T20:11:46Z | - |
dc.date.available | 2022-12-20T20:11:46Z | - |
dc.date.created | 2022-09-16 | - |
dc.date.issued | 2009-11 | - |
dc.identifier.issn | 0890-5339 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175894 | - |
dc.description.abstract | Objective: To determine whether locally applied tobramycin influences the ability of recombinant human bone morphogenetic protein 2 (rhBMP-2) to heal a segmental defect in the rat femur. Methods: The influence of tobramycin on the osteogenic differentiation of mesenchymal stein cells was first evaluated in vitro. For the subsequent, in vivo experiments, a 5-mm segmental defect was created in the right femur of each of 25 Sprague-Dawley rats and stabilized with an external fixator and four Kirschner wires. Rats were divided in four groups: empty control, tobramycin (11 mg)/absorbable collagen sponge, rhBMP-2 (11 p,g)/absorbable collagen sponge, and rhBMP-2/absorbable collagen sponge with tobramycin. Bone healing was monitored by radiography at 3 and 8 weeks. Animals were euthanized at 8 weeks and the properties of the defect were compared with the intact contralateral femur. Bone formation in the defect region was assessed by dual-energy x-ray absorptiometry, microcomputed tomography, histology, and mechanical testing. Results: Tobramycin exerted a dose-dependent inhibition of alkaline phosphatase induction and calcium deposition by mesenchymal stein cells cultured under osteogenic conditions. The inhibition was reversed in the presence of 500 ng/mL of rhBMP-2. Segmental defects in the rat femora failed to heal in the absence of rhBMP-2. Tobramycin exerted no inhibitory effects on the ability of rhBMP-2 to heal these defects and increased the bone area of the defects treated with rhBMP-2. Data obtained from all other parameters of healing, including dual-energy x-ray absorptiometry, microcomputed tomography, histology, and mechanical testing, were unaffected by tobramycin. Conclusions: Although our in vitro results suggested that tobramycin inhibits the osteogenic differentiation of mesenchymal stein cells, this could be overcome by rhBMP-2. Tobramycin did not impair the ability of rhBMP-2 to heal critical-sized femoral defects in rats. Indeed, bone area was increased by nearly 20% in the rhBMP-2 group treated with tobramycin. This study shows that locally applied tobramycin can be used in conjunction with rhBMP-2 to enhance bone formation at fracture sites. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Ability of Recombinant Human Bone Morphogenetic Protein 2 to Enhance Bone Healing in the Presence of Tobramycin: Evaluation in a Rat Segmental Defect Model | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Kichul | - |
dc.identifier.doi | 10.1097/BOT.0b013e3181b01b2f | - |
dc.identifier.scopusid | 2-s2.0-70350764949 | - |
dc.identifier.wosid | 000271313500002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ORTHOPAEDIC TRAUMA, v.23, no.10, pp.693 - 701 | - |
dc.relation.isPartOf | JOURNAL OF ORTHOPAEDIC TRAUMA | - |
dc.citation.title | JOURNAL OF ORTHOPAEDIC TRAUMA | - |
dc.citation.volume | 23 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 693 | - |
dc.citation.endPage | 701 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Orthopedics | - |
dc.relation.journalResearchArea | Sport Sciences | - |
dc.relation.journalWebOfScienceCategory | Orthopedics | - |
dc.relation.journalWebOfScienceCategory | Sport Sciences | - |
dc.subject.keywordPlus | OPEN FRACTURES | - |
dc.subject.keywordPlus | ANTIBIOTIC-THERAPY | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | FEMUR | - |
dc.subject.keywordPlus | BEADS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | RHBMP-2 | - |
dc.subject.keywordAuthor | tobramycin | - |
dc.subject.keywordAuthor | BMP-2 | - |
dc.subject.keywordAuthor | Segmental defect | - |
dc.subject.keywordAuthor | rat model | - |
dc.identifier.url | https://journals.lww.com/jorthotrauma/Fulltext/2009/11000/Ability_of_Recombinant_Human_Bone_Morphogenetic.2.aspx | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.